Stock Analysis

A Piece Of The Puzzle Missing From Systango Technologies Limited's (NSE:SYSTANGO) Share Price

When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 31x, you may consider Systango Technologies Limited (NSE:SYSTANGO) as a highly attractive investment with its 9.9x P/E ratio. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly reduced P/E.

Recent times have been quite advantageous for Systango Technologies as its earnings have been rising very briskly. One possibility is that the P/E is low because investors think this strong earnings growth might actually underperform the broader market in the near future. If that doesn't eventuate, then existing shareholders have reason to be quite optimistic about the future direction of the share price.

View our latest analysis for Systango Technologies

pe-multiple-vs-industry
NSEI:SYSTANGO Price to Earnings Ratio vs Industry May 30th 2024
Want the full picture on earnings, revenue and cash flow for the company? Then our free report on Systango Technologies will help you shine a light on its historical performance.

Is There Any Growth For Systango Technologies?

In order to justify its P/E ratio, Systango Technologies would need to produce anemic growth that's substantially trailing the market.

If we review the last year of earnings growth, the company posted a terrific increase of 87%. Pleasingly, EPS has also lifted 355% in aggregate from three years ago, thanks to the last 12 months of growth. Accordingly, shareholders would have probably welcomed those medium-term rates of earnings growth.

Comparing that to the market, which is only predicted to deliver 25% growth in the next 12 months, the company's momentum is stronger based on recent medium-term annualised earnings results.

With this information, we find it odd that Systango Technologies is trading at a P/E lower than the market. Apparently some shareholders believe the recent performance has exceeded its limits and have been accepting significantly lower selling prices.

What We Can Learn From Systango Technologies' P/E?

While the price-to-earnings ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of earnings expectations.

We've established that Systango Technologies currently trades on a much lower than expected P/E since its recent three-year growth is higher than the wider market forecast. There could be some major unobserved threats to earnings preventing the P/E ratio from matching this positive performance. It appears many are indeed anticipating earnings instability, because the persistence of these recent medium-term conditions would normally provide a boost to the share price.

Before you take the next step, you should know about the 2 warning signs for Systango Technologies that we have uncovered.

If you're unsure about the strength of Systango Technologies' business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.

Mobile Infrastructure for Defense and Disaster

The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.

Get the investor briefing before the next round of contracts

Sponsored On Behalf of CiTech

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NSEI:SYSTANGO

Systango Technologies

Provides software solutions in India, the United Kingdom, and the United States.

Outstanding track record with flawless balance sheet.

Weekly Picks

WO
MGPI logo
woodworthfund on MGP Ingredients ·

THE KINGDOM OF BROWN GOODS: WHY MGPI IS BEING CRUSHED BY INVENTORY & PRIMED FOR RESURRECTION

Fair Value:US$4034.1% undervalued
22 users have followed this narrative
4 users have commented on this narrative
5 users have liked this narrative
DO
Double_Bubbler
EVTL logo
Double_Bubbler on Vertical Aerospace ·

Why Vertical Aerospace (NYSE: EVTL) is Worth Possibly Over 13x its Current Price

Fair Value:US$6089.9% undervalued
23 users have followed this narrative
3 users have commented on this narrative
17 users have liked this narrative
TI
TickerTickle
ORCL logo
TickerTickle on Oracle ·

The Quiet Giant That Became AI’s Power Grid

Fair Value:US$389.8149.0% undervalued
43 users have followed this narrative
4 users have commented on this narrative
8 users have liked this narrative

Updated Narratives

IM
HOH logo
Imthetxarbi on High Arctic Overseas Holdings ·

Deep Value Multi Bagger Opportunity

Fair Value:CA$5.5579.6% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AG
Agricola
EXN logo
Agricola on Excellon Resources ·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
ST
stuart_roberts
UNCY logo
stuart_roberts on Unicycive Therapeutics ·

Unicycive Therapeutics (Nasdaq: UNCY) – Preparing for a Second Shot at Bringing a New Kidney Treatment to Market (TEST)

Fair Value:US$21.5370.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.4% undervalued
120 users have followed this narrative
11 users have commented on this narrative
22 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$250.3927.7% undervalued
963 users have followed this narrative
6 users have commented on this narrative
25 users have liked this narrative
RO
RockeTeller
SCZ logo
RockeTeller on Santacruz Silver Mining ·

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fair Value:CA$8688.0% undervalued
78 users have followed this narrative
8 users have commented on this narrative
21 users have liked this narrative